Patents by Inventor Sei Kwang Hahn

Sei Kwang Hahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10399291
    Abstract: The present invention provides a smart contact lens including a sensor capable of non-invasively sensing an eye disease in real time and a drug reservoir, and smart glasses for controlling the smart contact lens.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: September 3, 2019
    Assignee: PHI BIOMED CO., LTD.
    Inventors: Sei Kwang Hahn, Young Chul Sung, Beom Ho Mun, Keon Jae Lee, Dohee Keum, Su Jin Kim
  • Publication number: 20190076526
    Abstract: An upconversion nanoparticle includes at least one host selected from LiYF4, NaY, NaYF4, NaGdF4, and CaF3, at least one sensitizer selected from Sm3+, Nd3+, Dy3+, Ho3+, and Yb3+ doped in the at least one host, and at least one activator selected from Er3+, Ho3+, Tm3+, and Eu3+ doped in the at least one host. The upconversion nanoparticle is designed using a calculation from first principles to absorb light in the near-infrared wavelength range whose stability is ensured. Further, a hyaluronic acid-upconversion nanoparticle conjugate, in which the upconversion nanoparticle as described above is bonded to hyaluronic acid, is provided to be used in various internal sites with a hyaluronic acid receptor, particularly enables targeting, and increases an internal retention period and biocompatibility thereof.
    Type: Application
    Filed: September 13, 2017
    Publication date: March 14, 2019
    Inventors: Sei Kwang HAHN, Seulgi HAN, Hyun Woo LEE, Kyoo KIM
  • Patent number: 10092658
    Abstract: A transdermal delivery system of drug and a method of preparing the same are provided. More specifically, the invention can be a transdermal delivery system applied for various protein drugs such as vaccines and chemical drugs, because the drug delivery system has a biocompatibility, biodegradation property, transdermal delivery property, the safety of human body, maximum activity of protein drugs, good bio-conjugation efficiency and a long-term efficacy, a method of preparing the same and its use.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 9, 2018
    Assignee: PHI BIOMED CO., LTD.
    Inventors: Sei Kwang Hahn, Eung-Sam Kim, Jeonga Yang, Hyemin Kim, Kwan Yong Choi, Ji Hye Shin, Jung-Hee Kwon
  • Publication number: 20180036974
    Abstract: The present invention provides a smart contact lens including a sensor capable of non-invasively sensing an eye disease in real time and a drug reservoir, and smart glasses for controlling the smart contact lens.
    Type: Application
    Filed: April 25, 2016
    Publication date: February 8, 2018
    Inventors: Sei Kwang HAHN, Young Chul SUNG, Beom Ho MUN, Keon Jae LEE, Dohee KEUM, Su Jin KIM
  • Publication number: 20170274005
    Abstract: Disclosed is a complex for remedying or treating a retinal disease. The complex includes a hyaluronic acid or a derivative thereof, a carbon nanomaterial covalently bonded to the hyaluronic acid or the derivative thereof, and a photosensitizer bonded to the carbon nanomaterial. The complex for remedying or treating the retinal disease according to the present invention includes a hyaluronic acid-carbon nanomaterial-photosensitizer complex, thus selectively preventing the formation of active oxygen in retinal pigment epithelium cells for a relatively long period of time. Accordingly, the complex has excellent therapeutic efficacy and easily infiltrates into cells. Further, the present invention provides a composition for remedying or treating a retinal disease including the hyaluronic acid-carbon nanomaterial-photosensitizer complex.
    Type: Application
    Filed: December 20, 2016
    Publication date: September 28, 2017
    Inventors: Sei Kwang HAHN, Songeun Beack, Jun-Sub Choi, Choun-Ki Joo
  • Publication number: 20170067012
    Abstract: Provided are a hyaluronic acid derivative for liver-targeting delivery via intravenous injection of cells and a preparation method thereof. More particularly, provided are a preparation method of a hyaluronic acid derivative capable of modifying the surface of cells and also having biocompatibility, biodegradability, and liver-targeting deliver property, and use of the hyaluronic acid derivative prepared thereby as a liver-targeting cell delivery system.
    Type: Application
    Filed: August 26, 2016
    Publication date: March 9, 2017
    Inventors: Sei Kwang HAHN, Yun seop KIM, Won Ho KONG, Hyemin KIM
  • Publication number: 20160243246
    Abstract: The present invention relates to a hyaluronic acid-nucleic acid conjugate for the development of in vivo nucleic acid delivery system, and the development of nucleic acid delivery system using the same. Specifically, a hyaluronic acid-nucleic acid complex wherein a hyaluronic acid-alkylenediamine conjugate and nucleic acid are connected by a disulfide bond; a composition for nucleic acid delivery comprising the hyaluronic acid-nucleic acid complex as an active ingredient; a method for preparing the hyaluronic acid-nucleic acid complex; and a method for in vivo delivery of nucleic acid, comprising administering the hyaluronic acid-nucleic acid complex to a subject are provided.
    Type: Application
    Filed: May 11, 2016
    Publication date: August 25, 2016
    Inventors: Sei Kwang HAHN, Kitae Park, Jeonga Yang, Won Ho Kong, Min Young Lee
  • Publication number: 20160223842
    Abstract: One aspect of the present disclosure relates to a remotely controllable lens device. The lens device can include a lens material and a circuit physically coupled to the lens material. The circuit can be configured to be powered based on an energy signal from a power source to perform a function (e.g., release of drug, generation of electromagnetic radiation, detection of electromagnetic radiation, and/or control of an optical refractive property). For example, the power source can be an external power source and/or an auto-powered source. The external power source can be, for example, a power source that utilizes synchronized magnetic flux phase coupling (e.g., WiTricity). The auto-powered source can be provided on-site (e.g., on-chip) using a harvesting system (e.g., solar-cell, photo-cell, piezoelectric, etc.
    Type: Application
    Filed: September 9, 2014
    Publication date: August 4, 2016
    Inventors: Seok-Hyun Yun, Ehsan Kamrani, Sei Kwang Hahn, Hyemin Kim, Dohee Keum, Keon Jae Lee, Choun-Ki Joo
  • Publication number: 20160174885
    Abstract: The present invention relates to a microneedle, a sensor for detecting nitrogen monoxide, including the microneedle, a medical apparatus including the microneedle, and a manufacturing method thereof. The microneedle of the present invention may detect whether nitrogen monoxide is present or not by using electrochemical principles. Further, a change in concentration of nitrogen monoxide may be sensed in real time. The effects of detecting nitrogen monoxide may be used to diagnose cancer and forecast the size and growth degree of a tumor.
    Type: Application
    Filed: September 16, 2015
    Publication date: June 23, 2016
    Inventors: Sei Kwang HAHN, Dohee KEUM, Ho Sang JUNG, Hyemin KIM, Myeong Hwan SHIN
  • Patent number: 9221893
    Abstract: An HA-protein conjugate in which an HA-aldehyde derivative, in which an aldehyde group is introduced to a hyaluronic acid or a salt thereof, is conjugated to the N-terminus of a protein, and a method for preparing the same are provided. The HA-protein conjugate includes a protein drug exhibiting an excellent bioconjugation efficiency and long-term medicinal effects, and has excellent protein drug activities since the hyaluronic acid is specifically conjugated to the N-terminus of the protein. Also, since liver-targeting properties of the hyaluronic acid can be freely controlled by changing an aldehyde substitution rate of the HA-aldehyde derivative, the HA-protein conjugate can be effectively used as a protein drug for treating liver diseases, and also be useful in enabling long-term medicinal effects of a protein drug required to bypass the liver. Accordingly, the HA-protein conjugate can be effectively used for a drug delivery system of proteins.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: December 29, 2015
    Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Sei Kwang Hahn, Jeong A. Yang, Seung Kyu Yoon, Won Hee Hur, Ki Tae Park, Hye Min Kim, Hyun Tae Jung
  • Publication number: 20150297749
    Abstract: This disclosure relates to a low density lipoprotein-like cationic solid lipid nanoparticle targeting liver cells including parenchyma cells and non-parenchyma cells, a composition for liver target delivery, a composition for diagnosis and/or treatment of liver disease comprising the same, and a method for liver targeting of an active ingredient.
    Type: Application
    Filed: October 2, 2013
    Publication date: October 22, 2015
    Inventors: Sei Kwang HAHN, Won Ho KONG, Kitae PARK
  • Patent number: 9101669
    Abstract: Provided are a self-assembled conjugate of a host molecule containing compound and a guest molecule containing compound, a delivery composition of a bioactive material comprising the self-assembled conjugate and a bioactive material to be delivered, and a composition for tissue engineering containing the self-assembled conjugate and a cell.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: August 11, 2015
    Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Sei Kwang Hahn, Kimoon Kim, Hyuntae Jung, Jeong-A Yang, Kyeng Min Park
  • Publication number: 20150150994
    Abstract: The present invention relates to liver targeted drug delivery system using metal nanoparticles and a method for preparing the same. More particularly, the present invention relates to a method for preparing hyaluronic acid-gold nanoparticles/protein complex that can be used as liver targeted drug delivery system, by surface modifying gold nanoparticles having excellent stability in the body with hyaluronic acid having biocompatibility, biodegradability and liver tissue-specific delivery property, and binding protein drugs for treating liver diseases to the non-modified surface of the gold nanoparticles. And, the present invention relates to use of the hyaluronic acid-gold nanoparticles/protein complex for liver disease drug that may be safely applied to human body, increase drug efficacy duration time, and be effectively delivered to liver.
    Type: Application
    Filed: May 21, 2013
    Publication date: June 4, 2015
    Inventors: Sei Kwang Hahn, Min Young Lee, Jeonga Yang, Ho Sang Jung
  • Patent number: 9017712
    Abstract: The present invention relates to a filler composition for tissue reinforcement, including hyaluronic acid and alkylene diamine crosslinked hydrogel. The filler composition exhibits the positive physical properties required for tissue reinforcement, such as biocompatibility and swelling ability, as well as useful effects in that the same can remain in vivo for a long time.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: April 28, 2015
    Assignees: Shin Poong Pharmaceutical Co., Ltd., Postech Academy-Industry Foundation
    Inventors: Il Hwan Cho, Eui Jin Hwang, Moo Seok Seo, Young Soo Park, Byung Su Kim, Sei Kwang Hahn, Jung Kyu Park, Jun Seok Yeom, Eun Ju Oh
  • Publication number: 20150056254
    Abstract: A transdermal delivery system of drug and a method of preparing the same are provided. More specifically, the invention can be a transdermal delivery system applied for various protein drugs such as vaccines and chemical drugs, because the drug delivery system has a biocompatibility, biodegradation property, transdermal delivery property, the safety of human body, maximum activity of protein drugs, good bio-conjugation efficiency and a long-term efficacy, a method of preparing the same and its use.
    Type: Application
    Filed: February 7, 2013
    Publication date: February 26, 2015
    Applicant: PHI BioMed Co., Ltd.
    Inventors: Sei Kwang Hahn, Eung-Sam Kim, Jeonga Yang, Hyemin Kim, Kwan Yong Choi, Ji Hye Shin, Jung-Hee Kwon
  • Patent number: 8895069
    Abstract: The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: November 25, 2014
    Assignee: Postech Academy-Industry Foundation
    Inventors: Sei Kwang Hahn, Choun-Ki Joo, Yoon Keun Kim, Seung Kew Yoon, Eun Ju Oh, Ki Su Kim, Hyemin Kim, Kitae Park, Jeong-A Yang, Jun-Sub Choi, You Me Tae, Wonhee Hur
  • Patent number: 8747903
    Abstract: The present invention relates to a composition for nucleic acid delivery and a method for preparing the same, more particularly to a composition for nucleic acid delivery having excellent stability in the body environment and excellent intracellular delivery efficiency of nucleic acid, and enabling target directed delivery of nucleic acid, and a method for preparing the same.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: June 10, 2014
    Assignee: Postech Academy-Industry Foundation
    Inventors: Sei Kwang Hahn, Min-Young Lee, Kitae Park, Ki Su Kim, Hwiwon Lee
  • Patent number: 8703740
    Abstract: The present invention relates to a composition for preventing tissue adhesion which comprising a bio-compatible hyaluronic acid and a polymer compound. More specifically, the invention is a composition containing hyaluronic acid which has not been modified by a chemical crosslinking or other chemical modification a method for preparing the same, and a composition for adhesion prevention with superior efficacy. The composition of the present invention for preventing adhesion exhibits a physical barrier function and a new adhesion prevention function whereby thrombus formation, which is the basis of adhesion, is inhibited.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: April 22, 2014
    Assignees: Shin Poong Pharmaceutical Co., Ltd., Postech Academy-Industry Foundation
    Inventors: Il Hwan Cho, Sei Kwang Hahn, Eui Jin Hwang, Jang Sik Shin, Junseok Yeom
  • Publication number: 20140080897
    Abstract: The present invention relates to a hyaluronic acid-nucleic acid conjugate for the development of in vivo nucleic acid delivery system, and the development of nucleic acid delivery system using the same. Specifically, a hyaluronic acid-nucleic acid complex wherein a hyaluronic acid-alkylenediamine conjugate and nucleic acid are connected by a disulfide bond; a composition for nucleic acid delivery comprising the hyaluronic acid-nucleic acid complex as an active ingredient; a method for preparing the hyaluronic acid-nucleic acid complex; and a method for in vivo delivery of nucleic acid, comprising administering the hyaluronic acid-nucleic acid complex to a subject are provided.
    Type: Application
    Filed: September 16, 2013
    Publication date: March 20, 2014
    Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Sei Kwang HAHN, Kitae Park, Jeonga Yang, Won Ho Kong, Min Young Lee
  • Patent number: 8575332
    Abstract: The present invention provides long-acting sustained-release formulations of drugs such as proteins or peptides, which are injectable, completely biodegradable and safe, as well as ensuring efficient encapsulation of the drugs such as proteins or peptides without inhibiting their biological activity. It is possible to achieve injectable sustained-release formulations that ensure efficient encapsulation and long-term sustained release of drugs such as proteins or peptides while retaining their biological activity, when a solution containing a drug and a polysaccharide derivative such as hyaluronic acid having a crosslinkable functional group(s) or a salt thereof is dehydrated in microparticulate form starting from a dilute state, where crosslinking proceeds slowly, to reach a concentration which facilitates crosslinking, to thereby cause crosslinking reaction during concentration, so that the drug is encapsulated into the crosslinked polysaccharide to give drug-carrying microparticles.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 5, 2013
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Sei Kwang Hahn, Tsuyoshi Shimoboji